CervoMed Receives USPTO Notice of Allowance for Neflamapimod in Dementia with Lewy Bodies

On June 16, 2026, CervoMed Inc. received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering its lead drug candidate, neflamapimod. The patent specifically protects the use of neflamapimod for the treatment of dementia with Lewy bodies (DLB) in patients who do not exhibit substantial Alzheimer’s disease-like tau pathology. This strategic intellectual property milestone is expected to extend the company's patent protection for neflamapimod in this indication until 2042, excluding any potential future patent term extensions. Neflamapimod is an orally administered small molecule designed to inhibit the intra-neuronal enzyme p38 MAPK alpha, which plays a role in inflammation and synaptic dysfunction. This allowance strengthens CervoMed's competitive position as it continues to develop neflamapimod for neurodegenerative diseases.